425(scFv)-ETA'

425(scFv)-ETA' is a **recombinant immunotoxin** designed for targeted cancer therapy. It comprises a **single-chain variable fragment (scFv)** of an anti-EGFR antibody (425(scFv)), genetically fused to a truncated version of **Pseudomonas aeruginosa exotoxin A (ETA')**. The drug specifically binds to **epidermal growth factor receptor (EGFR)** overexpressed in malignant cells, especially certain **pancreatic carcinomas**, leading to selective cell killing via toxin-mediated inhibition of protein synthesis. **Mechanism of action**: The scFv component targets EGFR on tumor cells, delivering the exotoxin fragment intracellularly, which then catalyzes ADP-ribosylation of EF-2, blocking translation and inducing cell death. This approach enables selective cytotoxicity to EGFR-positive tumor cells while sparing normal tissues. Preclinical studies have demonstrated potent anti-tumor effects, particularly against disseminated metastatic pancreatic carcinoma in animal models, with intravenous administration reducing metastatic burden dramatically[1][2][4][5].

Other names

anti-EGF receptor immunotoxin 425(scFv)-ETA'recombinant anti-EGFR immunotoxin 425(scFv)-ETA'